{"id":"NCT04318548","sponsor":"GlaxoSmithKline","briefTitle":"Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age","officialTitle":"A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-25","primaryCompletion":"2023-11-21","completion":"2023-11-21","firstPosted":"2020-03-24","resultsPosted":"2025-03-04","lastUpdate":"2025-03-04"},"enrollment":945,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)","otherNames":["Bexsero"]},{"type":"BIOLOGICAL","name":"Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)","otherNames":["Menveo"]},{"type":"COMBINATION_PRODUCT","name":"Placebo","otherNames":["NaCl, saline solution"]}],"arms":[{"label":"MenB+MenACWY Group","type":"EXPERIMENTAL"},{"label":"MenB Group","type":"EXPERIMENTAL"},{"label":"MenACWY Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the immunogenicity, safety and tolerability of rMenB+OMV NZ and MenACWY vaccines when concomitantly administered to healthy subjects 16-18 years of age.","primaryOutcome":{"measure":"Number of Participants With Solicited Local Adverse Events (AEs) After the Vaccination With rMenB+OMV NZ","timeFrame":"During 7 days after the rMenB+OMV NZ vaccination at Day 1","effectByArm":[{"arm":"MenB+MenACWY Group","deltaMin":12,"sd":null},{"arm":"MenB Group","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":8,"exclusionCount":18},"locations":{"siteCount":53,"countries":["United States","Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":310},"commonTop":["Administration site pain","Headache","Fatigue","Nausea","Myalgia"]}}